Several companies and academic groups are harnessing AI and single-cell platforms to improve cancer diagnostics and drug discovery. One Biosciences, a French startup, raised €15 million to accelerate its RNA sequencing platform for oncology. Simultaneously, tools like OmicsTweezer integrate multi-omics and bulk data for improved tumor microenvironment analysis. Biotx AI leverages genome-wide association study data and machine learning to identify drug targets and patient subpopulations, partnering with emerging companies focused on neuropsychiatric disorders. These advances promise more precise clinical decision-making and therapeutic development.